Long-term results of combination chemotherapy with or without irradiation in small cell lung cancer

A 5- to 11-year follow-up

T. Ohnoshi, S. Hiraki, Katsuyuki Kiura, M. Fujii, K. Machida, Masahiro Tabata, T. Yonei, K. Kiura, H. Kamei, Y. Segawa, M. Tabata, T. Shibayama, K. Miyatake, T. Maeda, I. Kimura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Between April 1981 and December 1987, 148 patients with newly diagnosed small cell lung cancer (SCLC) were treated using combination chemotherapy with or without thoracic irradiation and prophylactic cranial irradiation (PCI) in a series of cooperative therapeutic trials. With a minimum follow-up of 4.7 years, 13 (9%) patients survived and were free of SCLC. These included 11 (15%) of 76 patients with limited disease and two (3%) of 72 patients with extensive disease. Three died without any evidence of SCLC (one each from second leukemia, non-small cell lung cancer, and unrelated disease). The remaining 10 (7%) patients are currently alive and free of SCLC beyond 4.7 years. Since late relapse beyond 5 years is a very rare event, these patients may have been cured. However, late toxicity of PCI must be kept in mind. Three among the 10 patients have suffered from neuropsychologic symptoms of varying degrees in severity. Although the long-term survival rate is a benchmark in the treatment of SCLC, modifications of therapy that may potentially avoid such toxicities should be considered hereafter.

Original languageEnglish
Pages (from-to)215-220
Number of pages6
JournalInternal Medicine
Volume32
Issue number3
Publication statusPublished - 1993

Fingerprint

Small Cell Lung Carcinoma
Combination Drug Therapy
Cranial Irradiation
Benchmarking
Non-Small Cell Lung Carcinoma
Leukemia
Thorax
Therapeutics
Survival Rate
Recurrence

Keywords

  • complications
  • late toxicities
  • long-term survivors

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Long-term results of combination chemotherapy with or without irradiation in small cell lung cancer : A 5- to 11-year follow-up. / Ohnoshi, T.; Hiraki, S.; Kiura, Katsuyuki; Fujii, M.; Machida, K.; Tabata, Masahiro; Yonei, T.; Kiura, K.; Kamei, H.; Segawa, Y.; Tabata, M.; Shibayama, T.; Miyatake, K.; Maeda, T.; Kimura, I.

In: Internal Medicine, Vol. 32, No. 3, 1993, p. 215-220.

Research output: Contribution to journalArticle

Ohnoshi, T, Hiraki, S, Kiura, K, Fujii, M, Machida, K, Tabata, M, Yonei, T, Kiura, K, Kamei, H, Segawa, Y, Tabata, M, Shibayama, T, Miyatake, K, Maeda, T & Kimura, I 1993, 'Long-term results of combination chemotherapy with or without irradiation in small cell lung cancer: A 5- to 11-year follow-up', Internal Medicine, vol. 32, no. 3, pp. 215-220.
Ohnoshi, T. ; Hiraki, S. ; Kiura, Katsuyuki ; Fujii, M. ; Machida, K. ; Tabata, Masahiro ; Yonei, T. ; Kiura, K. ; Kamei, H. ; Segawa, Y. ; Tabata, M. ; Shibayama, T. ; Miyatake, K. ; Maeda, T. ; Kimura, I. / Long-term results of combination chemotherapy with or without irradiation in small cell lung cancer : A 5- to 11-year follow-up. In: Internal Medicine. 1993 ; Vol. 32, No. 3. pp. 215-220.
@article{a396e698a66a42d89dcd6059d3a15aae,
title = "Long-term results of combination chemotherapy with or without irradiation in small cell lung cancer: A 5- to 11-year follow-up",
abstract = "Between April 1981 and December 1987, 148 patients with newly diagnosed small cell lung cancer (SCLC) were treated using combination chemotherapy with or without thoracic irradiation and prophylactic cranial irradiation (PCI) in a series of cooperative therapeutic trials. With a minimum follow-up of 4.7 years, 13 (9{\%}) patients survived and were free of SCLC. These included 11 (15{\%}) of 76 patients with limited disease and two (3{\%}) of 72 patients with extensive disease. Three died without any evidence of SCLC (one each from second leukemia, non-small cell lung cancer, and unrelated disease). The remaining 10 (7{\%}) patients are currently alive and free of SCLC beyond 4.7 years. Since late relapse beyond 5 years is a very rare event, these patients may have been cured. However, late toxicity of PCI must be kept in mind. Three among the 10 patients have suffered from neuropsychologic symptoms of varying degrees in severity. Although the long-term survival rate is a benchmark in the treatment of SCLC, modifications of therapy that may potentially avoid such toxicities should be considered hereafter.",
keywords = "complications, late toxicities, long-term survivors",
author = "T. Ohnoshi and S. Hiraki and Katsuyuki Kiura and M. Fujii and K. Machida and Masahiro Tabata and T. Yonei and K. Kiura and H. Kamei and Y. Segawa and M. Tabata and T. Shibayama and K. Miyatake and T. Maeda and I. Kimura",
year = "1993",
language = "English",
volume = "32",
pages = "215--220",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "3",

}

TY - JOUR

T1 - Long-term results of combination chemotherapy with or without irradiation in small cell lung cancer

T2 - A 5- to 11-year follow-up

AU - Ohnoshi, T.

AU - Hiraki, S.

AU - Kiura, Katsuyuki

AU - Fujii, M.

AU - Machida, K.

AU - Tabata, Masahiro

AU - Yonei, T.

AU - Kiura, K.

AU - Kamei, H.

AU - Segawa, Y.

AU - Tabata, M.

AU - Shibayama, T.

AU - Miyatake, K.

AU - Maeda, T.

AU - Kimura, I.

PY - 1993

Y1 - 1993

N2 - Between April 1981 and December 1987, 148 patients with newly diagnosed small cell lung cancer (SCLC) were treated using combination chemotherapy with or without thoracic irradiation and prophylactic cranial irradiation (PCI) in a series of cooperative therapeutic trials. With a minimum follow-up of 4.7 years, 13 (9%) patients survived and were free of SCLC. These included 11 (15%) of 76 patients with limited disease and two (3%) of 72 patients with extensive disease. Three died without any evidence of SCLC (one each from second leukemia, non-small cell lung cancer, and unrelated disease). The remaining 10 (7%) patients are currently alive and free of SCLC beyond 4.7 years. Since late relapse beyond 5 years is a very rare event, these patients may have been cured. However, late toxicity of PCI must be kept in mind. Three among the 10 patients have suffered from neuropsychologic symptoms of varying degrees in severity. Although the long-term survival rate is a benchmark in the treatment of SCLC, modifications of therapy that may potentially avoid such toxicities should be considered hereafter.

AB - Between April 1981 and December 1987, 148 patients with newly diagnosed small cell lung cancer (SCLC) were treated using combination chemotherapy with or without thoracic irradiation and prophylactic cranial irradiation (PCI) in a series of cooperative therapeutic trials. With a minimum follow-up of 4.7 years, 13 (9%) patients survived and were free of SCLC. These included 11 (15%) of 76 patients with limited disease and two (3%) of 72 patients with extensive disease. Three died without any evidence of SCLC (one each from second leukemia, non-small cell lung cancer, and unrelated disease). The remaining 10 (7%) patients are currently alive and free of SCLC beyond 4.7 years. Since late relapse beyond 5 years is a very rare event, these patients may have been cured. However, late toxicity of PCI must be kept in mind. Three among the 10 patients have suffered from neuropsychologic symptoms of varying degrees in severity. Although the long-term survival rate is a benchmark in the treatment of SCLC, modifications of therapy that may potentially avoid such toxicities should be considered hereafter.

KW - complications

KW - late toxicities

KW - long-term survivors

UR - http://www.scopus.com/inward/record.url?scp=0027265675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027265675&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 215

EP - 220

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 3

ER -